RZLT Key Statistics, Chart & Performance
The current stock price of RZLT is 3.13 USD. In the past month the price increased by 19.01%. In the past year, price decreased by -32.1%.
RZLT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RZLT. When comparing the yearly performance of all stocks, RZLT is a bad performer in the overall market: 94.9% of all stocks are doing better.
RZLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RZLT. No worries on liquidiy or solvency for RZLT as it has an excellent financial health rating, but there are worries on the profitability.
RZLT Financial Highlights
Over the last trailing twelve months RZLT reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 26.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.82% | ||
| ROE | -52.63% | ||
| Debt/Equity | 0 |
RZLT Forecast & Estimates
16 analysts have analysed RZLT and the average price target is 6.38 USD. This implies a price increase of 103.67% is expected in the next year compared to the current price of 3.13.
RZLT Ownership
RZLT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.585B | ||
| AMGN | AMGEN INC | 16.68 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.74 | 28.432B | ||
| INCY | INCYTE CORP | 13.62 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RZLT
Company Profile
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Company Info
REZOLUTE INC
275 Shoreline Drive, Suite 500
Redwood City CALIFORNIA 94065 US
CEO: Nevan Elam
Employees: 71
Phone: 16502064507
REZOLUTE INC / RZLT FAQ
What does RZLT do?
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Can you provide the latest stock price for REZOLUTE INC?
The current stock price of RZLT is 3.13 USD. The price increased by 0.32% in the last trading session.
Does RZLT stock pay dividends?
RZLT does not pay a dividend.
What is the ChartMill technical and fundamental rating of RZLT stock?
RZLT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does REZOLUTE INC have?
REZOLUTE INC (RZLT) currently has 71 employees.
What is the market capitalization of RZLT stock?
REZOLUTE INC (RZLT) has a market capitalization of 290.24M USD. This makes RZLT a Micro Cap stock.
What is the outstanding short interest for REZOLUTE INC?
The outstanding short interest for REZOLUTE INC (RZLT) is 22.77% of its float.